(Q53083316)

11 May 2018

title

Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib. (English)

1 reference

11 May 2018

1 reference

Hidenari Nagai

1

1 reference

11 May 2018

Takenori Kanekawa

2

1 reference

11 May 2018

Kojiro Kobayashi

3

1 reference

11 May 2018

Takanori Mukozu

4

1 reference

11 May 2018

Daigo Matsui

5

1 reference

11 May 2018

Teppei Matsui

6

1 reference

11 May 2018

Masahiro Kanayama

7

1 reference

11 May 2018

Noritaka Wakui

8

1 reference

11 May 2018

Kouichi Momiyama

9

1 reference

11 May 2018

Mie Shinohara

10

1 reference

11 May 2018

Koji Ishii

11

1 reference

11 May 2018

Yoshinori Igarashi

12

1 reference

11 May 2018

Yasukiyo Sumino

13

1 reference

11 May 2018

publication date

13 November 2013

1 reference

11 May 2018

Cancer Chemotherapy and Pharmacology

published in

1 reference

11 May 2018

volume

73

1 reference

11 May 2018

issue

2

1 reference

11 May 2018

page(s)

223-229

1 reference

11 May 2018

https://scigraph.springernature.com/pub.10.1007/s00280-013-2344-1

exact match

0 references

cites work

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Tumor necrosis factor receptor superfamily members and their ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Cytokines: coordinators of immune and inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Acquisition of lymphokine-producing phenotype by CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Targeting death-inducing receptors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

A mechanism of cell survival: sequestration of Fas by the HGF receptor Met.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2344-1

10.1007/S00280-013-2344-1

21 January 2018

Identifiers

DOI

1 reference

11 May 2018

PubMed ID

24220937

1 reference

11 May 2018